| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 43.06 | 9.0% |
| Total Income | 43.06 | 9.0% |
| Expenditure | 25.34 | 9.6% |
| PBT | 18.86 | 40.0% |
| Net Profit | 11.31 | 47.4% |
| OPM | 41.15% | 9.98pp |
| NPM | 26.26% | 19.17pp |
| EPS | 0.11 | 47.6% |
SBC Medical Reports Q1 2026 Revenue $43M, Down 9% YOY
14 May 2026 · 14 May, 4:26 pm
Summary
SBC Medical Group Holdings Incorporated announced its financial results for the three months ended March 31, 2026. Total revenues were $43 million, a 9% decrease year-over-year. Net income attributable to SBC Medical Group Holdings Incorporated was $11 million, a 47% decrease year-over-year. The net income margin was 26%, representing a year-over-year decrease of 19 percentage points. Yoshiyuki Aikawa, Chairman and Chief Executive Officer of SBC Medical, stated that the revenue decrease was primarily attributable to a strategic structural reform implemented in April 2025, involving a revision of the franchise fee structure.
Key Highlights
- 1
Total revenues were $43 million, representing a 9% year-over-year decrease.
- 2
Net income attributable to SBC Medical Group Holdings Incorporated was $11 million, representing a 47% year-over-year decrease.
- 3
Net income margin was 26% for the first quarter of 2026, representing a year-over-year decrease of 19 percentage points.
- 4
Earnings per share was $0.11 for the three months ended March 31, 2026, representing a 48% year-over-year decrease.
- 5
EBITDA was $18 million, representing a 26% year-over-year decrease.
- 6
EBITDA margin was 43% for the first quarter of 2026, representing a year-over-year decrease of 10 percentage points.
- 7
The number of franchise locations was 284 as of March 31, 2026, representing an increase of 33 locations from March 31, 2025.
Management Comments
Yoshiyuki Aikawa
For the first quarter of fiscal year 2026, SBC Medical reported revenue of $43 million, representing a 9% year-over-year decline. This decrease was primarily attributable to a strategic structural reform implemented in April 2025, involving a revision of the franchise fee structure. Excluding this structural change, the performance of our core business remained solid. In terms of profitability, our net income margin was 26%, and our EBITDA margin remained at a high level of 43%. Looking ahead, we will continue to promote our multi-brand strategy in the aesthetic dermatology field, expand our non-aesthetic medical business, and strengthen our operational foundation in overseas markets. In addition, we will pursue opportunities in the longevity market and further enhance our services through the utilization of AI, with the goal of building a sustainable and continuously growing healthcare platform.
Informational and educational content only. Not investment advice.